Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XB2001 plus trifluridine/tipiracil in metastatic colorectal cancer
NCT05201352Phase 2Active, not recruiting
- Sponsor
- Centre Georges-François Leclerc
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of XB2001 in colorectal cancer (metastatic) (mCRC), sponsored by Centre Georges-François Leclerc. Started Oct 2022; status: active, not recruiting.
02
Drugs
XB2001
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT05201352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201352.